Clinical trial
Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With…
NCT00203138 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT00203138 |
|---|---|
| Title | Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease |
| Official title | A Multicenter, Open-Label, Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline Mesylate in Patients With Parkinson's Disease |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | rasagiline mesylate |
| Enrollment | 306 |
| Start date | Jun 1, 2004 |
| Primary completion | Nov 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Apr 12, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: